

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

## MAY 29 1997

Mr. Foo Knon Pu 6J Medical Product SND BHD Lot 723, Batū 5 1/2, Jālan Kapar, 42100 Klang, Selangor Darul Ehsan MALAYSIA

Re: K971403

Trade Name: SMART - GLOVE® Powder-Free Latex

Examination Glove with Protein Content Labeling Claim

Regulatory Class: I Product Code: Lyy Dated: April 5, 1997 Received: April 15, 1997

Dear Mr. Foo Knon Pu:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Farts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of

the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 Apr (301) 443-6597 or at its internet address "http://www.fda.go//cdrh/dsmamain.html".

Sinderely yours

Timothy A. Ulatowski

Director

Division of Dental, Infection Control, and General Hospital Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

3.0 Indication For Use Statement.

## INDICATIONS FOR USE

Applicant

SJ MEDICAL PRODUCTS (M) SDN BHD

510K (Number)

K 971403

Davice Name

Smart Glove; Latex Patient Examination Gloves Powderfree,

50 megm or less water extractable protein.

indication for Use: This glove is disposable and is intended for medical purposes

that is worn on the examiner's hand to prevent contamination

between patient and examiner.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office Of Device Evaluation (ODE)

(Division Sign-Off)

Division of Dental, Infection Control,

and General Hospital Devices

510(k) Number <u>K971403</u>

Prescription Use (Per 21 CFR 801.109)

OR

Over-The-Counter Use

(Option Poremt 1-2-96)